HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.22 HKD | +2.50% |
|
+9.96% | +9.26% |
| Sales 2023 | 10.1B 1.39B 10.91B | Sales 2024 * | 11.81B 1.63B 12.76B | Capitalization | 94.41B 13.03B 102B |
|---|---|---|---|---|---|
| Net income 2023 | 3.28B 452M 3.54B | Net income 2024 * | 3.74B 516M 4.04B | EV / Sales 2023 | 8.4 x |
| Net cash position 2023 * | 17.31B 2.39B 18.7B | Net cash position 2024 * | 21.48B 2.96B 23.2B | EV / Sales 2024 * | 6.17 x |
| P/E ratio 2023 |
26
x | P/E ratio 2024 * |
24.8
x | Employees | 9,123 |
| Yield 2023 * |
0.68% | Yield 2024 * |
0.98% | Free-Float | 18.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +2.50% | ||
| 1 week | +9.96% | ||
| Current month | +11.24% | ||
| 1 month | +16.98% | ||
| 3 months | +38.20% | ||
| 6 months | +35.59% | ||
| Current year | +9.26% |
1 week
15.38
17.26
1 month
14.8817.26
Current year
11.1817.26
1 year
9.4117.26
3 years
9.4135.55
5 years
9.4146.70
10 years
9.4146.70
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Juan Zhong
CEO | Chief Executive Officer | 63 | 15-12-01 |
Sheng Li Zhong
SEC | Corporate Secretary | 56 | - |
Yan Wing Li
SEC | Corporate Secretary | 58 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guo Qiang Lin
BRD | Director/Board Member | 81 | 19-05-30 |
Sheung Wai Chan
BRD | Director/Board Member | 70 | 19-06-13 |
Dong Tao Yang
BRD | Director/Board Member | 67 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.00% | 4 M€ | -27.92% | ||
| 0.95% | 96 M€ | -3.91% | ||
| 0.92% | 2 M€ | -14.14% | ||
| 0.91% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 17.22 | +2.50% | 5 545 326 |
| 24-04-25 | 16.8 | 0.00% | 4,935,778 |
| 24-04-24 | 16.8 | +2.82% | 4,757,906 |
| 24-04-23 | 16.34 | +1.87% | 4,868,920 |
| 24-04-22 | 16.04 | +4.29% | 4,676,591 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT
More quotes
Hansoh Pharmaceutical Group Company Limited specializes in the development, manufacture and marketing of pharmaceutical products for the treatment of tumor, infectious, metabolic and autoimmune diseases. Net sales break down by revenue source as follows:
- sales of pharmaceutical products (99.1%);
- sales of research and development services (0.9%).
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
15.94
CNY
Average target price
17.47
CNY
Spread / Average Target
+9.59%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.26% | 12.71B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B |
- Stock Market
- Equities
- 3692 Stock
